Not the imaging program. One question, answered on a defined scope, where value is visible in weeks.
Independent central confirmation of imaging-based inclusion criteria before a patient is dosed. It does not touch your endpoint data, so it carries the lowest regulatory stakes of anything we do — and screen failures and wrongful enrollments are expensive, visible and quantifiable.
Central reads where blinded independent central review is not required. You get consistent, credentialed measurement and structured data; we prove our operational metrics on your study before anything registrational is on the table.
Imaging results still arrive as PDFs that someone on your team transcribes by hand. We deliver eCRF-ready structured data into your EDC directly. It changes nothing about how your trial runs, and it is the fastest way to see what the platform actually does.
We are not going to ask you to replace your imaging vendor on the first call. We are not going to ask you to adopt a platform, run an IT security review, or migrate a study mid-flight. Blinded independent central review, dual read and adjudication all run on ONIX AI — and none of them is where a sponsor should start with a vendor they have not worked with before.
Eligibility work becomes endpoint reads. Endpoint reads make us the natural choice when the registrational study needs a qualified central imaging vendor and the operational track record already exists. Nothing about the first engagement commits you to the second.
Our clinical team will scope your study in a short call. No commitment required.
1990 N California Blvd., 8th Floor
Walnut Creek, CA 94596
(844) 922-7468
hello@genphase.ai
Fill out the form and our clinical team will reach out within 24 hours.
By submitting this form, you agree to let GenPhase use the information provided to send relevant content about our services. You can unsubscribe at any time.